Pages that link to "Q43674732"
Jump to navigation
Jump to search
The following pages link to Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). (Q43674732):
Displaying 50 items.
- Reverse transcription of the HIV-1 pandemic (Q22242815) (← links)
- Adherence and drug resistance: predictions for therapy outcome (Q27477742) (← links)
- Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations (Q28235418) (← links)
- In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues (Q28343615) (← links)
- Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice (Q28343930) (← links)
- Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine (Q28344137) (← links)
- A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine (Q28379499) (← links)
- Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years (Q28379519) (← links)
- "Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice (Q28477270) (← links)
- Patterns of transmitted HIV drug resistance in Europe vary by risk group (Q28537726) (← links)
- Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro (Q28542490) (← links)
- Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. (Q29619254) (← links)
- Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee (Q33442370) (← links)
- Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients (Q33586790) (← links)
- Managing resistance to anti-HIV drugs: an important consideration for effective disease management. (Q33588535) (← links)
- Selection of drug-resistant HIV. (Q33594382) (← links)
- Evolutionary dynamics of HIV-induced subversion of the immune response (Q33683341) (← links)
- Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients (Q33699597) (← links)
- British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998). (Q33711667) (← links)
- A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host. (Q33728690) (← links)
- Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase (Q33737755) (← links)
- Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication (Q33743954) (← links)
- A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine (Q33782477) (← links)
- Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy (Q33782492) (← links)
- Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro (Q33782815) (← links)
- Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy (Q33784635) (← links)
- Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy (Q33825371) (← links)
- Human immunodeficiency virus drug resistance testing: state of the art in genotypic and phenotypic testing of antiretrovirals (Q33839756) (← links)
- Population genetic analysis of the protease locus of human immunodeficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay (Q33843999) (← links)
- Genotypic testing for human immunodeficiency virus type 1 drug resistance (Q33906239) (← links)
- Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase (Q33961507) (← links)
- Incidence and impact of resistance against approved antiretroviral drugs (Q33966248) (← links)
- A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC) (Q33976011) (← links)
- Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine (Q33977402) (← links)
- Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus (Q33981009) (← links)
- Inhibitors of HIV-1 reverse transcriptase (Q34050684) (← links)
- Antiretroviral therapy for human immunodeficiency virus infection in 1997 (Q34185841) (← links)
- Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase (Q34339657) (← links)
- Differential susceptibility of retroviruses to nucleoside analogues (Q34349394) (← links)
- Virus population dynamics, fitness variations and the control of viral disease: an update (Q34452529) (← links)
- Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. (Q34465037) (← links)
- Rapid emergence of protease inhibitor resistance in hepatitis C virus (Q34551913) (← links)
- The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studies (Q34625250) (← links)
- The HBV drug entecavir - effects on HIV-1 replication and resistance (Q34639926) (← links)
- Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. (Q34644794) (← links)
- The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase (Q34668716) (← links)
- Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity. (Q34677368) (← links)
- HIV-1 genotypic and phenotypic resistance (Q34876000) (← links)
- Antivirals against HIV-1. (Q34876093) (← links)
- 4'-C-methyl-2'-deoxyadenosine and 4'-C-ethyl-2'-deoxyadenosine inhibit HIV-1 replication (Q34933164) (← links)